

Drugs for treating auto immune disease

Ajay Goenka*

Wright State University, Boonshoft School of Medicine, 1 Children Plaza, USA

*Corresponding author: G.Ajay, Wright State University, Boonshoft School of Medicine, 1 Children Plaza, USA; E-mail: goenkaa@childrendayton.org

Received date: July 12, 2021; Accepted date: July 17, 2021; Published date: July 30, 2021

Citation: Ajay G (2021) Drugs for treating auto immune disease, Autoimmune Disord Vol.7 No.1:1

Copyright: © 2021 Ajay G. This is an open-access article distributed under the terms of the creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Introduction

In pharmacy most of the auto immune conditions use FDA approved medications for inventing new drugs in existing classes. And these drugs can be sometimes used for different auto immune conditions because these characteristics can be same and swelling can be triggered by same kind of auto immune disorders.

There are some immune suppressive drugs used to treat this kind of autoimmune diseases some of them are

Methotrexate

it is used at small doses to treat immune disorder disease it is antihumatic disease modifying drug.

Xeljanz

Tofacitinib citrate for moderately to severely active rheumatoid arthritis patients and this was FDA approved medication from Pfizer in may 2012. Who do not have success with methotrexate in 2018, and this was approved for adults for moderate and severity with ulcerative colitis. this is an option for Tofacitinib this is an option for patients who have failed in scientific therapies.

Olumiant

Olumiant 2 mg is successful in treating moderate-to-severe rheumatoid arthritis after methotrexate and TNF inhibitors failed therapies this is 3rd or 4th treatment to improve on older disease. it is used to treat other auto immune conditions such as lupus and psoriatic arthritis and this medication was approved by FDA on June 1 2018 from Ely Lilly Company.

Olumiant has several superior over biological arthritis treatments like it is a oral pill other than an injection. In clinical trials patients got early symptom relief in one week. It is the 2nd inhibitor accepted by FDA.

Cosentyx

This is the first human interleukin antagonist accepted for psoriatic arthritis and ankylosing spondylitis these scientists Joshua W. Gaborcik, PharmD, BCPS have , specialization in pharmacist-internal medicine It is also used to treat off-label rheumatoid arthritis, there are also some other type of antagoists on market but they are not FDA approved but for these three conditions cosentyx is treatable.

There are 100 different conditions existed for auto immune disorders these impacted many organ system damage and these require a specialists to direct them.

These conditions are also due to hereditary like if a mother is having rheumatoid arthritis then her aunt will have autoimmune thyroid disease and her daughter will be affected with lupus, and her cousin with inflammatory bowel disease in addition to these conditions the institute is conducting diagnostic tools and therapies research program.

Rheumatoid arthritis this disorder will affect multiple joints, includes hands, legs and also cause damage results in pain and functionality.

The first biological agent was accepted past 20 years ago which improved the treatment of RA and this work is made by blocking immune system. the more the medications the greater the treatment if one treatment is not effective they can prefer to other.

Auto-Immune Encephalitis is one type of disorder in neuro inflammatory anti NMDA receptor and other antibodies for causative agent led to guidelines for diagnosis and management, symptoms involves altered mental status, movable disorders, acute behavioral changes, psychosis, delirium, seizures, and insomnia.

In this article it provides information on the AI disorders and their clinical presentation, diagnostics measures and the drugs that are used to treat this type of diseases and their protocols based on present literature.

Acknowledgements

The author is thankful to the people who supported and

participated in this research. The de dermatology hospital who approved this study as well as the research and development team for their invaluable support during the study.

Conflict of interest

There is no conflict disclosed in this article.